Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

Autor: McMullen JR; Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia., Boey EJ; Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia., Ooi JY; Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia., Seymour JF; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Department of Medicine, University of Melbourne, Melbourne, VIC, Australia., Keating MJ; Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX., Tam CS; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
Jazyk: angličtina
Zdroj: Blood [Blood] 2014 Dec 11; Vol. 124 (25), pp. 3829-30.
DOI: 10.1182/blood-2014-10-604272
Databáze: MEDLINE